help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carrick, T. A.
Right arrow Articles by Zysk, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carrick, T. A.
Right arrow Articles by Zysk, J. R.

Endocrinology, Vol 136, 4701-4704, Copyright © 1995 by Endocrine Society

ARTICLES

A rapid and sensitive binding assay for growth hormone releasing factor

TA Carrick, B Bingham, CM Eppler, WR Baumbach and JR Zysk
Molecular & Cellular Biology Group, Agricultural Research Center, American Cyanamid Company, Princeton, New Jersey 08543, USA.

A binding assay for growth hormone releasing factor (GRF) has been developed using scintillation proximity assay (SPA) technology. Binding conditions were validated by several criteria. Equilibrium binding was attained within three hours at 22 degrees C in crude membrane fractions of HEK293 (293-P2) and GH4C1 (GH4-P1) cells transfected with the porcine GRF receptor. Saturation binding isotherms produced a KD of 296 pM and a Bmax of 4.7 pmols/mg membrane protein in 293-P2 cells. Cells not expressing the GRF receptor displayed no specific binding for the ligand. Competition binding curves produced the following rank order of potency for tested peptides: GRF analogs D-Ala2 = D-Arg2 (IC50 approximately 1 nM) >> PACAP > secretin, VIP (EC50 > 100 nM). Somatostatin (SRIF) binding was also adapted to the SPA format in a GH4C1 cell line transfected with the SRIF receptor subtype 2 (SSTR2) and in HEK293 cells transfected with the SRIF receptor subtype 5 (SSTR5). This assay represents a major improvement for binding measurements of these and potentially many other ligands for G-protein linked receptors, requiring no separation of bound from free hormone, allowing detailed pharmacological evaluations and enabling measurement of equilibrium binding in real time. In the 96-well format, it is suitable for high throughput screening.


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
W. R. Baumbach, T. A. Carrick, M. H. Pausch, B. Bingham, D. Carmignac, I. C. A. F. Robinson, R. Houghten, C. M. Eppler, L. A. Price, and J. R. Zysk
A Linear Hexapeptide Somatostatin Antagonist Blocks Somatostatin Activity In Vitro and Influences Growth Hormone Release in Rats
Mol. Pharmacol., November 1, 1998; 54(5): 864 - 873.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
R. W. Hipkin, J. Friedman, R. B. Clark, C. M. Eppler, and A. Schonbrunn
Agonist-induced Desensitization, Internalization, and Phosphorylation of the sst2A Somatostatin Receptor
J. Biol. Chem., May 23, 1997; 272(21): 13869 - 13876.
[Abstract] [Full Text] [PDF]

Home page
 J Biomol ScreenHome page
S. D. Kahl, F. R. Hubbard, G. S. Sittampalam, and J. M. Zock
Validation of a High Throughput Scintillation Proximity Assay for 5-HydroxytryptaminelE Receptor Binding Activity
J Biomol Screen, February 1, 1997; 2(1): 33 - 40.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society